RECRUITING

A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies

Description

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Conditions

Hematologic MalignanciesAdult
Talk to us

Related Conditions:

Hematologic MalignanciesAdult

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 As Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hematologic Malignancies

A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies

Condition
Hematologic Malignancies
Intervention / Treatment

-

Contacts and Locations

Denver

Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

Cincinnati

Oncology Hematology Cincinnati, Cincinnati, Ohio, United States, 45236

Nashville

SCRI - Transplant and Cellular Therapy Operations, Nashville, Tennessee, United States, 37203

Austin

Texas Oncology Austin Central, Austin, Texas, United States, 78731

Houston

MD Anderson Cancer Center, Houston, Texas, United States, 77030

Fairfax

Virginia Cancer Specialists, Fairfax, Virginia, United States, 22031

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adequate organ function
  • * CML in accelerated or blast phase
  • * Prior therapy with a similar mechanism of action to KQB198
  • * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • * History of interstitial lung disease
  • * Cardiac abnormalities

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Kumquat Biosciences Inc.,

Study Record Dates

2028-02